SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009936
Filing Date
2022-05-16
Accepted
2022-05-16 07:06:15
Documents
74
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-20220331.htm   iXBRL 10-Q 2067836
2 EX-10.1 fnch-ex10_1.htm EX-10.1 825897
3 EX-31.1 fnch-ex31_1.htm EX-31.1 20955
4 EX-31.2 fnch-ex31_2.htm EX-31.2 21260
5 EX-32.1 fnch-ex32_1.htm EX-32.1 21705
  Complete submission text file 0000950170-22-009936.txt   9224876

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20220331.xsd EX-101.SCH 69619
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20220331_lab.xml EX-101.LAB 539167
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20220331_pre.xml EX-101.PRE 389183
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fnch-20220331_cal.xml EX-101.CAL 41351
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fnch-20220331_def.xml EX-101.DEF 237852
68 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20220331_htm.xml XML 1438607
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 22925392
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences